Medicine composition for preventing and treating diabetes mellitus and application of medicine composition

A composition and technology for diabetes, applied in the directions of drug combination, urinary system diseases, metabolic diseases, etc., can solve the problems such as the prevention and treatment of diabetes that have not been reported with rebamipide

Active Publication Date: 2020-04-28
CHINA PHARM UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] There is no report on the combination of rebamipide and asiaticoside / its analogs in the prevention and treatment of diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for preventing and treating diabetes mellitus and application of medicine composition
  • Medicine composition for preventing and treating diabetes mellitus and application of medicine composition
  • Medicine composition for preventing and treating diabetes mellitus and application of medicine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1: The effect of the composition of rebamipide and asiaticoside and its analogs on blood sugar in NOD mice

[0049] 1. Experimental animals and experimental materials

[0050] SPF grade NOD mice, female, 4 weeks old, were purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0051] Rebapait: Aladdin, China

[0052] Asiaticoside: MedChemExpress Reagent Company, USA

[0053] Madecassoside: MedChemExpress Reagents, USA

[0054] Asiatic acid: Aladdin, China

[0055] Madecassic acid: Aladdin, China

[0056] Sodium carboxymethylcellulose: Aladdin, China

[0057] Solvent used in the control group: 0.5% CMC-Na

[0058] 2. Experimental process

[0059] After adaptive feeding for 1 week, the random blood glucose value of the tail vein of the mice was measured with a blood glucose meter at 9:00 a.m. every day for 3 consecutive measurements. According to the random blood sugar and body weight, the mice were randomly divided into groups and dosed, administered o...

Embodiment 2

[0065] Embodiment 2: Drug effect evaluation of the pharmaceutical composition of the present invention on type 1 diabetes NOD mice

[0066] 1. Experimental animals

[0067] SPF grade NOD mice, female, 4 weeks old, were purchased from Beijing Huafukang Biotechnology Co., Ltd. All animals were raised in an IVC environment, provided with sufficient feed and drinking water, maintained a circadian rhythm of 12 hours of light and 12 hours of darkness, with a temperature of 25±2°C and a humidity of 50%-70%.

[0068] All animal experiments were performed in accordance with the relevant experimental regulations of China Pharmaceutical University, and the experimental process followed animal ethics.

[0069] 2. Main reagents

[0070] Rebapait: Aladdin, China

[0071] Asiaticoside: MedChemExpress Reagent Company, USA

[0072] Sodium carboxymethylcellulose: Aladdin, China

[0073] 3. Experimental process

[0074] After the NOD mice were adaptively fed for 1 week, the random blood gl...

Embodiment 3

[0125] Embodiment 3: The drug effect evaluation of pharmaceutical composition of the present invention to type 2 diabetes db / db mice

[0126] 1. Experimental animals

[0127] SPF-grade db / db mice, male, 4 weeks old, were purchased from the Institute of Model Animals, Nanjing University.

[0128] 2. Main reagents

[0129] Metformin: Aladdin, China

[0130] Rebapait: Aladdin, China

[0131] Asiaticoside: MedChemExpress Reagent Company, USA

[0132] Sodium carboxymethylcellulose: Aladdin, China

[0133] 3. Experimental process

[0134] (1) Grouping and administration:

[0135] The db / db mice were adaptively fed for 1 week, and then randomly grouped according to their fasting blood glucose and body weight:

[0136] A. Solvent control group: 0.5% CMC-Na, 10 rats;

[0137] B. Metformin group: 150mg / kg, 10 rats;

[0138] C. Rebamipide group: 150mg / kg, 10 rats;

[0139] D. Asiaticoside group: 60mg / kg, 10 rats;

[0140] E. Combined low-dose group: rebamipide 75mg / kg+ asiatic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine composition for preventing and treating diabetes mellitus and application of the medicine composition. The medicine composition comprises a component (i) rebamipideand / or an analog thereof, and a component (ii) asiaticoside and / or an analog thereof. The medicine composition disclosed by the invention is capable of remarkably reducing the blood sugar and the incidence rate of an NOD (no obesity diabetes) mouse, improving the response capability to a glucose load, relieving pancreas islet inflammation, inhibiting expression of a Th1 type cell factor, promotingexpression of a Th2 type cell factor, reducing the death rate and taking functions of preventing and treating diabetes mellitus into play, and has wide application prospects.

Description

technical field [0001] The invention relates to a pharmaceutical composition for preventing and treating diabetes and its application, belonging to the technical field of medicines. Background technique [0002] Diabetes mellitus (DM) is a group of lifelong metabolic diseases characterized by chronic hyperglycemia caused by multiple etiologies. It manifests as long-term hyperglycemia, and damage to large blood vessels and microvessels further endangers the heart, brain, kidney, peripheral nerves, eyes, and feet. With the development of society, the improvement of people's living standards and the change of lifestyle, diabetes is gradually increasing globally, and has become the third chronic non-infectious disease that affects human health after malignant tumors and cardiovascular diseases. disease. Both the World Health Organization (WHO) and the American Diabetes Association (ADA) divide diabetes into four categories: type 1 diabetes (T1DM), type 2 diabetes (T2DM), speci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7024A61K31/4704A61P3/10A61P13/12A61P9/14A61P9/12A61P9/10A61P9/00A61P1/16
CPCA61K31/4704A61K31/7024A61P1/16A61P3/10A61P9/00A61P9/10A61P9/12A61P9/14A61P13/12A61K2300/00
Inventor 吴亮崔雪婷牟畅吴晓明
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap